bioRxivCancer BiologyPreprint
Transcriptional Response to Tumor Mutational Burden Is Consistent Across Cancer Types
Karen Y. ShihiD, Onn BrandmaniD, Monte M. WinslowiD, Dmitri A. PetroviD
Abstract
Tumor mutational burden (TMB) shapes tumor transcriptional state, but studies typically describe this response as an average effect pooled across cancer types. Whether that average reflects a consistent response present within individual cancer types, or is an artifact of merging heterogeneous, tissue-specific responses, remains unresolved. Here we analyze ~9,100 tumors across 32 TCGA cancer types to test whether the transcriptional response to TMB is genuinely consistent across tissues. We construct a TMB axis score from TMB-associated genes upregulated with increasing TMB, yielding a sample-level measure of response strength, and subsequently decompose it at the component and pathway/complex levels. The pooled transcriptional response to TMB stays largely consistent within each cancer type, and no single cancer is driving the pooled signal. This consistency was also observed at the component and pathway/complex levels. These findings support TMB as a promising tissue-agnostic signature, with implications for tissue-agnostic therapeutic targeting.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types
- Universality of distribution of tumor mutation burden - a biomarker for the tumor evolution and disease risk
X. Li, S. Sinha, D. Thirumalai·bioRxiv·Mar 3, 2022
- Imprints of tumor mutation burden on chromosomes and relation to cancer risk in humans: A pan-cancer analysis
X. Li, D. Thirumalai·bioRxiv·Apr 20, 2020
- APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohorts
KM Butler, Dhanusha Yesudhas, … Abdul Rouf Banday·bioRxiv·Jul 13, 2026
- Cancer Type-Dependent Correlations between TP53 Mutations and Antitumor Immunity
- ecTMB: a robust method to estimate and classify tumor mutational burden
Lijing Yao, Yao Fu, … Hugo Y. K. Lam·Scientific ReportsPeer-reviewed·Mar 18, 2020